954397-95-6

Usage

Molecular Structure

Naphthalene carboxylic acid core with various functional groups, including a piperazine ring, an imidazole ring, an ethoxyphenyl group, and a methylphenyl group.

Functional Groups

Presence of imidazole and piperazine moieties, which are commonly found in pharmaceutical compounds.

Potential Applications

Medicinal chemistry, specifically in the design of drugs targeting specific receptors or enzymes.

Further Research

Necessary to determine the compound's specific pharmacological properties and potential uses.

Upstream product

• 954382-59-3 1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazole-4-carboxylic acid 
• 1061517-90-5 C₁₅H₁₆N₂O₂ 
• 621-33-0 m-phenetidine 
• 104-85-8 para-methylbenzonitrile 
• 954397-98-9 methyl 3-(4-{[1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazol-4-yl]carbonyl}-1-piperazinyl)-1-naphthoate 
• 954382-60-6 N-(3-ethoxyphenyl)-4-methylbenzamidine 
• 954382-61-7 ethyl 1-(3-ethoxyphenyl)-2-(4-methylphenyl)-1H-imidazole-4-carboxylate 

Relevant academic research and scientific papers

Discovery of imidazole carboxamides as potent and selective CCK1R agonists

High-throughput screening revealed diaryl pyrazole 3 as a selective albeit modest cholecystokinin 1 receptor (CCK1R) agonist. SAR studies led to the discovery and optimization of a novel class of 1,2-diaryl imidazole carboxamides. Compound 44, which was profiled extensively, showed good in vivo mouse gallbladder emptying (mGBE) and lean mouse overnight food intake (ONFI) reduction activities.

A rapid, large-scale synthesis of a potent cholecystokinin (CCK) 1R receptor agonist

The development of a scalable synthesis of a potent cholecystokinin (CCK) IR receptor agonist is described. The focus on a rapid short-term delivery rather than longer-term development allowed for the preparation of multihundred gram quantities to support